These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29355809)

  • 21. Prediction of O(6)-methylguanine-DNA methyltransferase promoter methylation status in IDH-wildtype glioblastoma using MRI histogram analysis.
    Liu X; Han T; Wang Y; Liu H; Zhou J
    Neurosurg Rev; 2024 Jun; 47(1):285. PubMed ID: 38907038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region.
    Xing Z; Zhang H; She D; Lin Y; Zhou X; Zeng Z; Cao D
    Acta Radiol; 2019 Dec; 60(12):1663-1672. PubMed ID: 31084193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
    Eoli M; Menghi F; Bruzzone MG; De Simone T; Valletta L; Pollo B; Bissola L; Silvani A; Bianchessi D; D'Incerti L; Filippini G; Broggi G; Boiardi A; Finocchiaro G
    Clin Cancer Res; 2007 May; 13(9):2606-13. PubMed ID: 17473190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10 years of age.
    Ferris SP; Goode B; Joseph NM; Kline CN; Samuel D; Gupta N; Bollen A; Perry A; Mueller S; Solomon DA
    Acta Neuropathol; 2016 Jul; 132(1):153-5. PubMed ID: 27161253
    [No Abstract]   [Full Text] [Related]  

  • 26. Predictors of Tumor Dynamics Over a 6-Week Course of Concurrent Chemoradiotherapy for Glioblastoma and the Effect on Survival.
    Ong WL; Stewart J; Sahgal A; Soliman H; Tseng CL; Detsky J; Chen H; Ho L; Das S; Maralani P; Lipsman N; Stanisz G; Perry J; Lim-Fat MJ; Atenafu EG; Lau A; Ruschin M; Myrehaug S
    Int J Radiat Oncol Biol Phys; 2024 Nov; 120(3):750-759. PubMed ID: 38561051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
    Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
    J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anatomical localization of p53 mutated tumors: A radiographic study of human glioblastomas.
    Zhang T; Wang Y; Fan X; Ma J; Li S; Jiang T; Wang L
    J Neurol Sci; 2014 Nov; 346(1-2):94-8. PubMed ID: 25130928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
    Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
    World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
    Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
    J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
    Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
    Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
    J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular heterogeneity of glioblastomas: does location matter?
    Denicolaï E; Tabouret E; Colin C; Metellus P; Nanni I; Boucard C; Tchoghandjian A; Meyronet D; Baeza-Kallee N; Chinot O; Figarella-Branger D
    Oncotarget; 2016 Jan; 7(1):902-13. PubMed ID: 26637806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
    Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
    Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leptomeningeal metastases in isocitrate dehydrogenase-wildtype glioblastomas revisited: Comprehensive analysis of incidence, risk factors, and prognosis based on post-contrast fluid-attenuated inversion recovery.
    Park YW; Jang G; Kim SB; Choi K; Han K; Shin NY; Ahn SS; Chang JH; Kim SH; Lee SK; Jain R
    Neuro Oncol; 2024 Oct; 26(10):1921-1932. PubMed ID: 38822538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
    Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
    Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic features of small cell glioblastomas.
    Takeuchi H; Kitai R; Hosoda T; Yamada S; Hashimoto N; Kikuta K; Shimizu Y; Kimura H
    J Neurooncol; 2016 Apr; 127(2):337-44. PubMed ID: 26725094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas.
    Yang F; Yang P; Zhang C; Wang Y; Zhang W; Hu H; Wang Z; Qiu X; Jiang T
    Oncotarget; 2017 Jun; 8(26):42974-42982. PubMed ID: 28496000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.